Dashboard PDUFA PDUFA History Dilution Watch Downside Radar Missed Milestones Earnings Big Movers Blog

🎤 Upcoming Biotech Conferences

Loading conferences...
Free to browse, no account needed Follow the companies behind these drugs with free AI briefings, catalyst countdowns and dilution alerts.

Casimersen · Amondys 45, SRP-4045

Oligonucleotide (Antisense oligonucleotide) · Gene silencing: dystrophin (DMD) pre-mRNA, exon 45 (DMD) · developed by Sarepta Theraps

Approved FDA, Feb 2021
SRPT Developer
3 Registered trials

What is Casimersen?

Casimersen is an antisense oligonucleotide that binds exon 45 of dystrophin pre-mRNA, causing the exon to be excluded during mRNA processing. This is intended to allow production of an internally truncated dystrophin protein. It is studied in Duchenne muscular dystrophy in patients with mutations amenable to exon 45 skipping.

Summary written with AI from the sources listed at the end of this page.

At a glance

Also known as
Amondys 45, SRP-4045, AMONDYS 45
Drug type
Oligonucleotide (Antisense oligonucleotide)
Targets
dystrophin (DMD) pre-mRNA, exon 45 (DMD)
Mechanism
Gene silencing: dystrophin (DMD) pre-mRNA, exon 45 (DMD)
Pathways
dystrophin pre-mRNA splicing (exon 45 skipping), internally truncated dystrophin production
Therapy area
Musculoskeletal, Neurology
Developer
Sarepta Theraps Inc (SRPT)
FDA status
Approved as Amondys 45 (February 25, 2021), NDA213026 · FDA label
UNII
X8UHF7SX0R

✅ FDA-approved uses

From the indications section of the FDA label (version of Jan 9, 2026). Read the full label for the exact wording, limitations and safety information.

🧪 Clinical trials

TrialPhaseConditionStatusSponsor
NCT03532542 Phase 3 Duchenne Muscular Dystrophy Terminated SRPT
NCT02500381 Phase 3 Duchenne Muscular Dystrophy Completed SRPT
NCT04179409 Phase 2 Duchenne Muscular Dystrophy Completed SRPT

Trials of the companies BioRadar tracks, from ClinicalTrials.gov, most advanced phase first.

Conditions studied

Duchenne Muscular Dystrophy

Other drugs acting on DMD

More from Sarepta Theraps

Sources

Updated Nov 1, 2026. Something wrong or missing? Report it on the SRPT page.

Follow SRPT, the company behind Casimersen

See SRPT's upcoming FDA decisions, trial readouts, cash runway and dilution risk, updated every day from SEC, FDA and ClinicalTrials.gov filings.

SRPT catalysts and pipeline →
Data: FDA (Drugs@FDA, Purple Book, DailyMed), NIH (NCI Thesaurus, GSRS, RxNorm), ClinicalTrials.gov • Informational purposes only, not medical or investment advice. • All drugs A–Z

This data is for informational purposes only, not investment advice. BioRadar does not provide buy/sell recommendations. Past performance does not guarantee future results. Always do your own due diligence.